Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease

用于莱姆病快速血清诊断的芯片即时检测实验室

• 批准号: 9052111
• 负责人: Maria Gomes-Solecki
• 金额: $ 100万
• 依托单位: IMMUNO TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-03 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9052111
• 关键词: Affect; Aftercare; Algorithms; Antibiotics; Antibodies; Antigens; Area; Arthritis; Bedside Testings; Biological Assay; Biological Markers; Blood; Blood Volume; Borrelia burgdorferi; Caring; Centers for Disease Control and Prevention (U.S.); Collaborations; Data; Detection; Development; Devices; Diagnosis; Diagnostic; Diagnostic tests; Disease; Disease Outcome; Disease Progression; Early Diagnosis; Early treatment; Enzyme-Linked Immunosorbent Assay; Extramural Activities; Fingers; Health; Heart; Human; In Vitro; Injury; Joints; Laboratories; Lead; Letters; Lyme Disease; Microfluidics; Nervous system structure; Phase; Refractory; Reproducibility; Running; Sensitivity and Specificity; Serodiagnoses; Serological; Serum; Skin; Staging; Symptoms; Syndrome; System; Technology; Testing; Time; United States; Validation; Vector-transmitted infectious disease; base; body system; cost; cross reactivity; design; improved; micro-total analysis system; outcome forecast; performance tests; point of care; polypeptide; prevent; prototype; standard of care; validation studies

DESCRIPTION: Caused by Borrelia burgdorferi, Lyme disease (LD) can affect the skin, heart, joints or nervous system leading to an array of largely non-specific symptoms that overlap with those of other debilitating illnesses. Disease progression can lead to development of conditions with unfavorable prognosis such as antibiotic-refractory arthritis or Post- Treatment Lyme disease Syndrome (PTLDS). Early diagnosis and treatment is key to improving disease outcomes. Current assays do not discriminate between early and late stages of the disease and cannot predict prognosis. We propose to use ultrasensitive microfluidics technology to develop the first quantitative rapid lab-on-a-chip point of care (POC) assay for the serodiagnosis of Lyme disease. The proposed POC test will provide sensitive and definitive detection and differentiation of early- and late- stage Lyme disease in a single test. It is a versatile and informative first-tier assay which can evolve to replace the current bi-serologic two-tier standard of care.

产品说明：莱姆病（LD）由伯氏疏螺旋体引起，可以影响皮肤，心脏，关节或神经系统，导致一系列与其他衰弱性疾病重叠的非特异性症状。疾病进展可导致具有不利预后的病症的发展，例如难治性关节炎或治疗后莱姆病综合征（PTLDS）。早期诊断和治疗是改善疾病结局的关键。目前的检测方法不能区分疾病的早期和晚期，也不能预测预后。我们建议使用超灵敏的微流体技术来开发第一个定量的快速芯片实验室护理点（POC）检测，用于莱姆病的血清诊断。拟议的POC测试将提供敏感和明确的检测和区分早期和晚期莱姆病在一个单一的测试。它是一种通用的、信息丰富的一级检测试剂盒，可发展为替代当前的双血清学两级标准品 照顾。

项目成果

Borrelia burgdorferi BBI39 Paralogs, Targets of Protective Immunity, Reduce Pathogen Persistence Either in Hosts or in the Vector.

伯氏疏螺旋体 BBI39 旁系同源物是保护性免疫的目标，可减少宿主或载体中病原体的持续存在。

• DOI: 10.1093/infdis/jix036
• 发表时间: 2017
• 期刊: The Journal of infectious diseases
• 作者: Singh,Preeti;Verma,Deepshikha;Backstedt,BrianT;Kaur,Simarjot;Kumar,Manish;Smith,AlexisA;Sharma,Kavita;Yang,Xiuli;Azevedo,JoséF;Gomes-Solecki,Maria;Buyuktanir,Ozlem;Pal,Utpal
• 通讯作者: Pal,Utpal